By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Scios Inc. (Acquired By Johnson & Johnson) 

6500 Paseo Padre Parkway

Fremont  California  94555  U.S.A.
Phone: 510-248-2500 Fax: 510-248-2389

Scios Inc. is a biopharmaceutical company developing novel drugs for the potential treatment of cardiovascular and inflammatory diseases. We are distinguished by our disease-based technology platform which integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and rationally design small-molecule compounds. Scios employs approximately 427 people and is headquartered in Sunnyvale, California.

Scios has received approval from the U.S. Food and Drug Administration to market NatrecorÃ’ (nesiritide) for the treatment of patients with acutely decompensated congestive heart failure who have shortness of breath (dyspnea) at rest or with minimal activity. Natrecor is a new drug class, human B-type Natriuretic Peptides, made available as a therapeutic in the United States.

The other lead product in the Company's pipeline is SCIO-469. We have completed two Phase I trials evaluating the safety of SCIO-469. An oral inhibitor of p38 kinase, SCIO-469 is being developed for the potential treatment of rheumatoid arthritis. A Phase II clinical trial evaluating SCIO-469 in rheumatoid arthritis patients is scheduled to begin in the first quarter of 2002.

Key Statistics

Ownership: Public

Web Site: Scios Inc. (Acquired By Johnson & Johnson)
Employees: 427
Symbol: JNJ


Company News
Scios Inc. (JNJ) Announces Agreement with Department of Justice Regarding NATRECOR(R) 10/6/2011 11:13:44 AM
Study Finds Scios Inc. (JNJ)'s Heart Failure Drug, Natrecor, Ineffective 7/7/2011 7:07:27 AM
Scios Inc. (JNJ) Announces Results of ASCEND Heart Failure Study at the Scientific Sessions of the American Heart Association 11/15/2010 11:34:58 AM
Two Drugs For Heart Failure Show Mixed Results; Novartis Pharmaceuticals Corporation (NVS)'s Diovan Should Be Used More Often And Scios Inc. (JNJ)'s Natrecor Should Not Be Used At All, VA Medical Center And Baylor University Research Shows 5/22/2008 7:36:39 AM
Scios Inc. (JNJ) Announces Enrollment of First Patients in ASCEND-HF Trial in Acute Heart Failure 6/8/2007 11:08:48 AM
Scios Inc. (JNJ) Announces Selection Of Independent Executive Committee And Planned Protocol Design For The ASCEND-HF Landmark International Outcomes Trial Of NATRECOR(R) (nesiritide) 11/13/2006 2:59:52 PM
Investigators Report New Renal, Mortality And Safety Data; Johnson & Johnson (JNJ) Says Natrecor Meets Goals In Midstage Trial 9/11/2006 11:37:21 AM
Johnson & Johnson (JNJ) Unit Orders Heart Failure Drug Test 9/8/2006 9:00:36 AM
The Day In Review: Pfizer Inc. (PFE) Returns Indiplon To Neurocrine Biosciences, Inc. (NBIX) 6/23/2006 6:02:29 PM
Johnson & Johnson (JNJ) To Shut Down Fremont Scios Inc. (JNJ) Unit; Lays Off 500 Workers From Scios And ALZA Corporation (JNJ) 6/23/2006 11:49:59 AM